American Journal of Cardiology
Volume 104, Issue 2 , Pages 234-239 , 15 July 2009

Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14)

  • Robert Spanheimer, MD

      Affiliations

    • Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois
    • Corresponding Author InformationCorresponding author: Tel: 224-554-6261; fax: 224-554-7842
    • ,
  • D. John Betteridge, MD

      Affiliations

    • University College Hospital, London, United Kingdom
    • ,
  • Meng H. Tan, MD

      Affiliations

    • Eli Lilly & Company, Indianapolis, Indiana
    • ,
  • Ele Ferrannini, MD

      Affiliations

    • Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy
    • ,
  • Bernard Charbonnel, MD

      Affiliations

    • University Hospital, Nantes, France
    • ,
  • PROactive Investigators

      Affiliations

    • Conflicts of interest: Drs. Betteridge, Tan, and Charbonnel have served on advisory boards, received grant support, and/or received honoraria for consulting services from Takeda Pharmaceutical Company. Dr. Ferrannini served as an external consultant to the PROactive Steering Committee for 2007 and 2008. Dr. Spanheimer is an employee of Takeda Pharmaceuticals North America. Dr. Tan was an employee of Eli Lilly & Company when the PROactive study was conducted.

Received 17 November 2008 ,Revised 8 March 2009 ,Accepted 8 March 2009.

References 

  1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  2. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A PROactive Study Group. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? (Study design and baseline characteristics of 5238 patients). Diabetes Care. 2004;27:1647–1653
  3. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716–730
  4. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458–2464
  5. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  6. Goldberg RB. Impact of thiazolidinediones on serum lipoprotein levels. Curr Atheroscler Rep. 2006;8:397–404
  7. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(suppl):7B–12B
  8. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl):M8–M14
  9. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction (The Framingham study). Arteriosclerosis. 1988;8:207–211
  10. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197
  11. Khan M, Xu Y, Edwards G, Urquhart R, Mariz S. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicenter, randomised studies. Int J Clin Pract. 2004;58:907–912
  12. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323–1332
  13. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia. 2006;49:527–537

 This study is registered as an International Standard Randomized Controlled Trial (NCT00174993) and was funded by Takeda Pharmaceutical Company, Deerfield, Illinois, and Eli Lilly & Company, Indianapolis, Indiana.

PII: S0002-9149(09)00733-4

doi: 10.1016/j.amjcard.2009.03.023

American Journal of Cardiology
Volume 104, Issue 2 , Pages 234-239 , 15 July 2009

Article Tools

* Image Usage & Resolution